ARPM considers the time frame for the pilot project on labeling medicines is feasible

18 September 2017

On September 13, the official website of Russia’s Kommersant newspaper published an article "Medicines do not keep the brand," misinterpreting the words of the general director of the Russian Pharmaceutical Manufacturers (ARPM) Viktor Dmitriev.

The article stated:

"Members of the Association of the Russian Pharmaceutical Manufacturers (ARPM), including Stada, AstraZeneca, Bayer, suggest adjourning the turnover period to total marking of medicines from 2019 to 2021. They are afraid that 80% of manufacturers need more time to install the necessary equipment by the appointed time and unmarked medicines will be illegal at the market. "

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK